FibroGen, Inc. (FGEN)
| Market Cap | 784.63M |
| Revenue (ttm) | 257.71M |
| Net Income (ttm) | -281.47M |
| Shares Out | 93.30M |
| EPS (ttm) | -3.14 |
| PE Ratio | n/a |
| Forward PE | 61.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 853,569 |
| Open | 8.93 |
| Previous Close | 9.20 |
| Day's Range | 8.22 - 9.11 |
| 52-Week Range | 7.81 - 30.13 |
| Beta | 0.79 |
| Analysts | Sell |
| Price Target | 13.67 (+62.5%) |
| Earnings Date | May 9, 2022 |
About FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human mon...
Financial Performance
In 2021, FibroGen's revenue was $235.31 million, an increase of 33.46% compared to the previous year's $176.32 million. Losses were -$290.02 million, 53.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for FGEN stock is "Sell." The 12-month stock price forecast is 13.67, which is an increase of 62.54% from the latest price.
News
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen Reports First Quarter 2022 Financial Results
SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company's recent developments.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating FibroGen, Inc.
Wilmington, Delaware--(Newsfile Corp. - May 5, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockholders...
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigat...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigatio...
FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen to Report First Quarter 2022 Financial Results
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopat...
- 356 IPF Patients Enrolled -
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2021 and provided an update on the company's recent d...
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroG...
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th...
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright ...
FibroGen Exercises Exclusive License Option for HiFiBiO's CCR8 Program
SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class thera...
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of Long-Term Stockholders and E...
NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fibrogen, Inc. (NASDAQ: FGEN) on behalf of...
FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
FibroGen Reports Third Quarter 2021 Financial Results
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2021 and provided an update on the Company's recent developments.
FibroGen to Present at Upcoming Investor Conferences
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following health...
FibroGen to Report Third Quarter 2021 Financial Results
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also co...
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Societ...
What's Happening With FibroGen Stock?
Last month, we discussed that FibroGen (NASDAQ: FGEN) stock price could rebound over a one-month period after falling 6% in a week, based on the Trefis Machine Learning Engine. However, FGEN stock has s...
Why FibroGen Fell by More Than 9% on Wednesday
A noted investment bank takes a dimmer view of the company's stock.
Will FibroGen Stock Rebound After Positive Roxadustat Data?
The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a large sell-off in FGEN stock, ...
FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study
FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.
FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial
FibroGen Inc (NASDAQ: FGEN) has announced topline data from WHITNEY Phase 2 study of roxadustat for chemotherapy-induced anemia (CIA). The trial met the primary efficacy endpoint of maximum change in he...